Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients

Diabetic Medicine

Volumn 23, Issue 6, 2006, Pages 675-680

  Lajer, M ^a   Schjoedt, K J ^a   Jacobsen, P ^a   Tarnow, L ^a   Parving, H H ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Aldosterone synthase; CYP11B2; Diabetic nephropathy; Polymorphism; Type 1 diabetes

Indexed keywords

ALBUMIN; ALDOSTERONE SYNTHASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

ADULT; AGE; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CAUCASIAN; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE PHENOTYPE INTERACTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADULT; ALDOSTERONE SYNTHASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STATISTICS, NONPARAMETRIC;

EID: 33744821124     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01871.x     Document Type: Article

References (33)

1. Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998 41 : 745 759.
2. Borch-Johnsen K Nørgaard K Hommel E Mathiesen ER Jensen JS Deckert T. et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992 41 : 719 722.
3. Quinn M Angelico MC Warram JH Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996 39 : 940 945.
4. Seaquist ER Goetz FC Rich S Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989 320 : 1161 1165.
5. Earle K Walker J Hill C Viberti G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992 326 : 673 677.
6. Fagerudd JA Tarnow L Jacobsen P Stenman S Nielsen FS Fernholm KJ et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998 47 : 439 444.
7. Tarnow L Rossing P Nielsen FS Fagerudd JA Poirier O Parving H-H. Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000 23 : 30 33.
8. White PC. Mechanisms of disease - disorders of aldosterone biosynthesis and action. N Eng J Med 1994 331 : 250 258.
9. Hommel E Parving H-H Mathiesen E Edsberg B Damkjaer-Nielsen M Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986 293 : 467 470.
10. Lewis EJ Hunsicker LG Bain RP Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993 329 : 1456 1462.
11. Brenner BM Cooper ME de Zeeuw D Keane WF Mitch WE Parving H-H et al. Study I: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001 345 : 861 869.
12. Lewis EJ Hunsicker LG Clarke WR Berl T Pohl MA Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001 345 : 851 860.
13. Parving H-H Lehnert H Bröchner-Mortensen J Gomis R Andersen S Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med 2001 345 : 870 878.
14. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001 19 : 829 842.
15. Epstein M Buckalew V Martinez F Altamirano J Roniker B Kleiman J et al. Eplerenone-021,I: anti-proteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens, 2002 15 : 24A.
16. Sato A Hayashi K Naruse M Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003 41 : 64 68.
17. Curnow KM Tusie-Luna MT Pascoe L Natarajan R Gu JL Nadler JL et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 1991 5 : 1513 1522.
18. White PC Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995 21 : 437 442.
19. Fardella CE Rodriguez H Montero J Zhang G Vignolo P Rojas A et al. Genetic variation in P450c11AS in Chilean patients with low renin hypertension. J Clin Endocrinol Metab 1996 81 : 4347 4351.
20. Davies E Holloway CD Ingram MC Inglis GC Friel EC Morrison C et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999 33 : 703 707.
21. Ganapathipillai S Laval G Hoffmann IS Castejon AM Nicod J Dick B et al. CYP11B2-CYP11B1 haplotypes associated with decreased 11β-hydroxylase activity. J Clin Endocrinol Metab 2005 90 : 1220 1225.
22. Brand E Chatelain N Mulatero P Féry I Curnow K Jeunemaitre X et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998 32 : 198 204.
23. Sarzani R Salvi F Dessí-Fulgheri P Catalini R Mazzara D Cola G et al. Aldosterone synthase alleles and cardiovascular phenotype in young adults. J Hum Hypertens 2003 17 : 859 864.
24. Tiago AD Badenhorst D Nkeh B Candy GP Brooksbank R Sareli P et al. Impact of renin-angiotensin-aldosterone system gene variants on the severity of hypertension in patients with newly diagnosed hypertension. Am J Hypertens 2003432004 16 : 1006 1010.
25. Parving H-H Mauer M Ritz E. Diabetic nephropathy. In : Brenner BM ed. The Kidney. WB Saunders, 2004 : 1777 1818.
26. Jacobsen P Tarnow L Carstensen B Hovind P Poirier O Parving H-H. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol, 2003 14 : 2843 2850.
27. Borch-Johnsen K Nørgaard K Hommel E Mathiesen ER Jensen JS Deckert T et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992 41 : 719 722.
28. Tarnow L Cambien F Rossing P Nielsen FS Hansen BV Lecerf L et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995 44 : 489 494.
29. Kupari M Hautanen A Lankinen L Koskinen P Virolainen J Nikkila H et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998 97 : 569 575.
30. Russo P Siani A Venezia A Iacone R Russo O Barba G et al. Interaction between the C(-344) T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 2002 20 : 1785 1792.
31. Kurland L Melhus H Karlsson J Kahan T Malmqvist K Ohman P et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Am J Hypertens 2002 15 : 389 393.
32. Kosachunhanun N Hunt SC Hopkins PN Williams RR Jeunemaitre X Corvol P et al. Genetic determinants of non-modulating hypertension. Hypertension 2003 42 : 901 908.
33. Ortlepp JR Hanrath P Mevissen V Kiel G Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002 445 : 151 152.